Over the past 10 years, cancer immunotherapy has made significant progress in multiple
cancer types and has been gradually been applied to clinical cancer care, in which the …

Cancers of the oral cavity cause significant cancer-related death worldwide. While survival
rates have improved in recent years, new methods of treatment are being investigated to …

Abstract Background The presence of Programmed Death-Ligand 1 protein (PD-L1) in oral
squamous cell carcinoma (OSCC) may indicate an ability to evade immune response and …

Immunohistochemical assessment with combined positive score (CPS) of programmed
death-ligand 1 (PD-L1) is the prerequisite for administration of checkpoint inhibitor therapy …

The expression of programmed cell death-ligand 1 (PD-L1) is being used as a predictive
biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Our …

Background Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge
rapidly in recent years, especially for new targeted therapies and immunotherapies …

Great attention has been attached to explore the association between oral bacteria and oral
cancer. Recently, four common inhabitants of oral cavity, Porphyromonas gingivalis …

Head and neck cancer has high heterogeneity with poor prognosis, and emerging
researches have been focusing on the prognostic markers of head and neck cancer. PD-L1 …

Amongst the chief targets of immune-checkpoint inhibitors (ICIs), namely the Programmed
cell death protein 1 (PD-1)/PD-Ligands (Ls) axis, most research has focused on PD-L1 …

Cancer progression can be understood as the result of deregulation of tumors' immune
microenvironments. Recent studies of the alterations of microenvironments highlight their …